NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today that it has entered into a definitive agreement to acquire Genoptix, Inc. for $125 million in cash and 1 million shares of NeoGenomics common stock. Genoptix is a leading clinical oncology laboratory, specializing in hematology and solid tumor testing, with an …
Centurion Service Group today announced that 1315 Capital has acquired a majority stake in the company. Centurion Service Group (Centurion) is the market leader for selling surplus medical equipment and operates the world’s largest medical equipment auction house from its four locations in the United States.
Solsys Medical, LLC (“Solsys”) (formerly known and doing business as Soluble Systems, LLC) (“Solsys Medical”), which markets TheraSkin®, a cellular and tissue-based product for regenerative wound healing, announced today that it has partnered with Healogics, the nations largest provider of advanced chronic wound care services, to be a part of the new Healogics iSupply program, …
Genoptix, Inc., a leading oncology diagnostic laboratory, announces the immediate availability of a proprietary, FDA-authorized BCR-ABL MRDx® TFR Monitoring Test for patients with chronic myeloid leukemia (CML) being treated with Tasigna®(nilotinib). The test is commercially available in the U.S. exclusively through Genoptix. The BCR-ABL MRDx® TFR Monitoring Test is the only diagnostic test authorized by …
Colorescience®, a prominent dermatologist-recommended skin health cosmetics company, has earned its second award from O, The Oprah Magazine Fall Beauty O-Ward, for the new Sunforgettable® Total Protection™ Face Shield SPF 50. Launched in April of 2018, Face Shield is the first liquid SPF product for the face in the company’s portfolio that features their patented …
After a successful cross-country collaboration with the HydraFacial Nation World Tour, Colorescience®, the leading dermatologist-recommended skincare and cosmetics company, is excited to announce the next partnership between the two companies beginning in August 2018 that fully integrates Colorescience®’s into the PERK experience.
Colorescience® is pleased to announce that the US Patent and Trademark Office (USPTO) has granted a patent (US Patent No. 9,956,163) for the company’s innovative LUMIRA™ formulation, a clinically tested, highly effective complex that addresses the appearance of skin discoloration, found in the 3-in-1 treatment product, Even Up® Clinical Pigment Perfector®.
Solsys Medical, LLC (“Solsys”) (formerly known and doing business as Soluble Systems, LLC) (“Soluble Systems”), which markets TheraSkin®, a cellular and tissue-based product for regenerative wound healing, announced today the appointment of Arti Balar Masturzo, M.D as its Chief Medical Officer.
Insight Medical Systems has teamed up with Onkos Surgical, Inc. to explore opportunities to apply Insight Medical’s ARVIS™ (Augmented Reality Visualization and Information System) in musculoskeletal oncology. The companies are working on a pilot project to assess the technology for use in tumor surgery.
Encore Dermatology Inc. announces today the availability of a new topical product, IMPOYZ Cream, indicated for the treatment of moderate to severe plaque psoriasis in patients 18 years of age or older. IMPOYZ Cream is the only FDA-approved high-potency topical corticosteroid with 0.025% clobetasol propionate.
Genoptix, Inc., a leading oncology diagnostic laboratory today announced that Rosetta Genomics’ stockholders have approved the acquisition of Rosetta Genomics by Genoptix. Genoptix will immediately begin marketing, selling and distributing the complete Rosetta Genomics portfolio and will ensure the uninterrupted availability of these important products for physicians and patients. Genoptix previously purchased Rosetta Genomics’ precision …
Colorescience® is proud to announce the addition of two new members to its Board of Directors, David Olsen and Ty Stiklorius.